mind body glp 1 Dual-action obesity drug rewires brain circuits for appetite MindBody Activated Lifestyle
Description
Extended clinical trials and real-world data are crucial to understand their lasting impact on weight, metabolic health, and potential side effects
.jpg?width=1200&length=1200&name=One%20Page%20Mock%20Up%20(2).jpg)
In the trials, participants who took the highest dose reduced their A1C values by an average of 2.0%
Two of the most significant risk factors for the development of MASLD are obesity and type 2 diabetes both of which are positively impacted by GLP1 receptor agonists and are FDA-approved indications for GLP1 receptor agonist utilization
However, this is optional for plans, not mandated
